Insights into the pharmaceutical production at Boehringer Ingelheim

The work in the pharmaceutical production of Boehringer Ingelheim is different. It is innovative, because we produce active pharmaceutical ingredients for diseases with high unmet medical need. It is meaningful, because it secures the medical supply of million patients worldwide. And it is challenging, because we are continuously improving our processes and relying on state-of-the-art technology.

As a globally operating pharmaceutical company, Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals. For decades, we are committed to improving the life of patients. We stand for innovative, top-quality medical therapies.

We rely on a strong production network

We produce our pharmaceuticals ourselves - from the production of active pharmaceutical ingredients to the finished pharmaceuticals. To minimize the influence of external factors, we rely for example on a strong production network, which allocates important steps and technologies within the production processes to more than one facility. Thanks to our digital processes, we are very transparent and flexible.

#StrongerTogether

As in other industries, the impact of the COVID-19 pandemic put our production and supply chains to test. As a company, it is our duty to ensure the protection and health of our employees. We have therefore further supplemented our safety measures in production with special COVID-19 measures. And we have adjusted our production processes to meet the growing global demand. Teamwork and the great dedication of our more than 15,000 colleagues in production around the world were a decisive factor in this endeavor.

Our Pharmaceutical Production

Continuous development and improvement

Boehringer Ingelheim produces active pharmaceutical ingredients and finished pharmaceuticals at more than two dozen sites worldwide for its three business units Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. The production sites are state-of-the-art and feature complex and unique manufacturing technologies. We have a long-term commitment to our sites and invest continuously in their further development. In doing so, we also strengthen regional economies and the local infrastructure.

© 2020, 2021, Peter Ginter

To protect the purity of the active pharmaceutical ingredient our colleagues work with special handling and containment measures

Our colleagues face the challenge of adapting the manufacturing process of new active pharmaceutical ingredients to the requirements of large-scale industrial production.